Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Sales (2016 - 2025)

Historic Return on Sales for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 0.02%.

  • Zevra Therapeutics' Return on Sales rose 89600.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42%, marking a year-over-year increase of 40800.0%. This contributed to the annual value of 4.47% for FY2024, which is 27900.0% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Return on Sales of 0.02% as of Q3 2025, which was up 89600.0% from 2.88% recorded in Q2 2025.
  • Zevra Therapeutics' Return on Sales' 5-year high stood at 3.59% during Q4 2022, with a 5-year trough of 19.62% in Q2 2022.
  • Moreover, its 5-year median value for Return on Sales was 1.05% (2021), whereas its average is 2.51%.
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -201400bps in 2022, then soared by 193200bps in 2023.
  • Over the past 5 years, Zevra Therapeutics' Return on Sales (Quarter) stood at 1.05% in 2021, then skyrocketed by 443bps to 3.59% in 2022, then plummeted by -143bps to 1.54% in 2023, then crashed by -93bps to 2.98% in 2024, then skyrocketed by 99bps to 0.02% in 2025.
  • Its Return on Sales was 0.02% in Q3 2025, compared to 2.88% in Q2 2025 and 0.15% in Q1 2025.